Harrow Health Inc

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harrow Health Inc anticipates breakout year in 2023 post-successful Q4

Harrow Health Inc's Q4 2022 call showcased a strong performance, emphasizing strategic acquisitions and growth prospects for 2023. While challenges in expense management and pricing strategies exist, the company's leadership is focused on maximizing opportunities and delivering value to stakeholders.

Harrow Health Inc excels in Q1, poised for ophthalmic market leadership

Harrow Health Inc's Q1 2023 earnings call highlighted robust financial performance, a strategic roadmap for market leadership in ophthalmic pharmaceuticals, and positive early indicators for product success. While facing challenges in product formulations and margins, the company's focus on customer feedback and commercialization strategies presents significant growth opportunities.

Harrow Health Inc reports revenue growth driven by key products

Harrow Health Inc's Q2 2023 performance reflects positive revenue growth and a strong market position driven by VEVYE and IHEEZO.
While facing challenges with leverage ratios and net equity, the company's flexible approach and growth outlook offer opportunities for improvement.
Strengthened by recent acquisitions and stakeholder support, Harrow Health is poised for continued growth and market competitiveness.
Investors should monitor the company's financial leverage, revenue drivers, and market strategies for insights into its future performance.

Harrow Health Inc achieves record revenues, eyes market expansion

Harrow Health Inc reported strong financial performance with record revenues and growth in key metrics.
While facing challenges in certain product revenues and the compounding business, the company is optimistic about new product opportunities.
Management's confidence in the company's prospects and goals reflects a positive outlook for stakeholders.

Harrow Health Inc reports stellar Q4 results and eyes market dominance

Harrow Health Inc's Q4 2023 performance reflects robust financial growth, strategic successes, and a resilient market position, setting the stage for continued expansion.
While facing challenges such as a cyber attack impact and operational hurdles, the company's strengths in strategic focus, pricing strategy, and market opportunities position it well for future success.
With a clear vision for growth, a commitment to value creation, and a focus on market dominance in key segments, Harrow Health Inc is poised for sustained growth and profitability in the coming year.

Harrow Health Inc (HROW) achieves record Q3 revenue growth

Harrow Health Inc (HROW) reported strong Q3 performance with record revenue, driven by VEVYE and IHEEZO. The company is focused on sustainable growth, long-term vision, and value creation for stakeholders. Challenges include temporary inventory shortages and limited direct-to-consumer advertising plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for oc

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Harrow Health, Inc. (NASDAQ:HROW ) Q2 2022 Earnings Conference Call August 9, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll - Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann Sahil Kazmi - B. Riley Securities Nathan Weinstein - Aegis Capital Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to Harrow Health's Second Quarter 2022 Earnings Conference Call.

Harrow Health, Inc.'s (HROW) CEO Mark Baum on Q2 2022 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference to be held on August 17, 2022. Harrow Health's pre-recorded presentation will be available via a

Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced results for the second quarter ended June 30, 2022. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “We are pleased with both our financial and operational perform

Harrow Health Announces Second Quarter 2022 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for the second quarter ended June 30, 2022, on Tuesday, August 9, 2022, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors”

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these m

Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States

Century Casinos

Chicken Soup for the Soul Entertainment

VAALCO Energy

GEE Group

vTv Therapeutics

These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared first on InvestorPlace.

7 Mighty Micro-Cap Stocks That Could Be Future Moonshots

Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43% YOY. Harrow entered an opaque market filled with middle men and dissatisfied ophthalmologists. Harrow understands their customers, solves their pain points, and has earned their trust. This is a deep moat.

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

Harrow Health's (NASDAQ:HROW ) Q1 2022 Earnings Conference Call May 5, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll - Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalmann Nathan Weinstein - Aegis Capital Sahil Kazmi - B. Riley Securities Operator Good afternoon, and welcome to Harrow Health's Q1 2022 Earnings Conference Call.

Harrow Health's (HROW) CEO Mark L. Baum on Q1 2022 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the first quarter ended March 31, 2022. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “Our first quarter financial and operational results, combined with our internal forecasts and the opportunities we are currently pursuing, have validated our belief th

Harrow Health Announces First Quarter 2022 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced top-line results of its phase 1 pharmacokinetics (PK) study of MELT-210. MELT-210 is a fixed dose of 3 mg of midazolam formulated in a proprietary rapidly dissolving sublingual tablet technology for procedural sedation. The study was conducted in 23 patients and compared 3 mg and 6 mg MELT-210 sublingual midazol

Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference, which will be held virtually on Wednesday, April 27, 2022, at 2:00 p.m. ET/1:00 p.m. CT. A live webcast of the presentation will be available on the Company's website, www.harrowinc.com

Harrow Health to Participate in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced the appointments of Perry J. Sternberg and Marty Makary, M.D., M.P.H. to the Company's Board of Directors, effective immediately. The Company also announced that Robert J. Kammer has resigned from Harrow Health's Board of Directors, effective immediately. With these changes, Harrow Health's Board will consist of six members. “It is a pleasure to welcome Perry and Mart

Harrow Health Announces Appointments to Its Board of Directors

Harrow Health's (HROW) CEO Mark L. Baum on Q4 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced results for the fourth quarter and year ended December 31, 2021. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrowinc.com. “The fourth quarter of 2021 represents our sixth consecutive quarter of record performance in many key financial and operational metrics, providing a soli

Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the addition of Brad Osborne as Chief Financial Officer. Osborne brings 20 years of extensive finance and accounting experience. Prior to joining Melt Pharmaceuticals, Osborne worked for 10 years with Precigen, Inc. (formerly Intrexon Corporation), a Nasdaq-listed discovery and clinical-stage biopharmaceutical comp

Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to di

Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for AMP-100, the Company's drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act (PDUFA) target action date of October 16, 2022. In

Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company overview at the Aegis Capital Corp. Virtual Conference to be held on February 23-25, 2022. To access Harrow Health's presentation, which will begin on Thursday, February 24, 2022, at 3:30 p.m. ET/2:30 p.m. CT, please click on the link to the Aegis conference on

Harrow Health to Present at Aegis Virtual Conference

Taysha Gene Therapies

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Two Insider Moonshots Rising on Sudden Buying

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic‑focused healthcare company, today announced that its inaugural 2022 Corporate Transparency Report is now available under the Investors section of the Company's website, harrowinc.com. The report focuses on Harrow Health's commitment to initiatives that it believes support its mission to make innovative, sight-saving medications more accessible and affordable. “I am pleased to present our 2022 Corporate Transpar

Harrow Health Publishes Corporate Transparency Report

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022. Harrow Health's pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com, beginning at 7:00 a.m. ET on Monday, Janu

Harrow Health to Participate in H.C. Wainwright BioConnect Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two investigational new drug applications (INDs) with the U.S. Food and Drug Administration (FDA) for two sublingual, IV-free, non‑opioid formulations – MELT-210 (midazolam) for procedural sedation and MELT-400 (ketamine) for pain. Both formulations have been developed in an exclusive partnership with

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and

News for Harrow Health Inc Stock (HROW)